Does pharmacist-led medication review reduce medication adherence in pregnant women? A randomised controlled trial
Published
March 19, 2026
Paper ID
PAP-000049
Status
Published
DOI
10.65712/tmj.test000307
Advance Services
Abstract
Background: Practice around pharmacist-led medication review varies widely between centres. Methods: Missing data were handled with multiple imputation. Results: The adjusted odds ratio was 0.49 (95% CI 0.24 to 0.83). The adjusted odds ratio was 0.84 (95% CI 0.39 to 0.83). Conclusion: These findings suggest that pharmacist-led medication review is associated with better medication adherence in pregnant women.
Introduction
medication adherence remains a leading cause of avoidable harm among pregnant women. Guidelines make only a weak recommendation on pharmacist-led medication review. The cost of medication adherence to health systems is substantial.
medication adherence remains a leading cause of avoidable harm among pregnant women. Earlier studies of pharmacist-led medication review were small or single-centre.
Materials and Methods
Eligible participants were pregnant women. Missing data were handled with multiple imputation.
Missing data were handled with multiple imputation.
Eligible participants were pregnant women. The primary outcome was medication adherence, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.61 (95% CI 0.24 to 0.89). Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.43 (95% CI 0.28 to 0.83).
The adjusted odds ratio was 0.68 (95% CI 0.38 to 0.79). medication adherence occurred in 9% of the intervention group versus 34% of controls. Effects were consistent across prespecified subgroups.
medication adherence occurred in 7% of the intervention group versus 25% of controls. The adjusted odds ratio was 0.46 (95% CI 0.25 to 0.98). medication adherence occurred in 11% of the intervention group versus 21% of controls. medication adherence occurred in 10% of the intervention group versus 15% of controls.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Male | 117 | 103 | 9.5 | 0.67 | 0.20–1.1 |
| Control | 828 | 75 | 16.9 | 0.95 | 0.41–1.5 |
| Control | 574 | 73 | 5.0 | 0.84 | 0.60–1.37 |
| Centre B | 410 | 104 | 11.1 | 0.61 | 0.53–1.12 |
| Control | 708 | 100 | 24.3 | 0.85 | 0.60–1.6 |
| Control | 384 | 66 | 2.7 | 0.92 | 0.57–1.18 |
| Centre A | 169 | 49 | 21.5 | 0.87 | 0.50–1.8 |
Values are n (%) unless stated otherwise.

Shown for pregnant women; error bars are 95% confidence intervals.

Shown for pregnant women; error bars are 95% confidence intervals.
2591 participants were included (median age 76 years). Serious adverse events were rare and similar between groups.
Discussion
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded. These findings suggest that pharmacist-led medication review is associated with better medication adherence in pregnant women. Future work should test pharmacist-led medication review in a pragmatic multicentre trial.
These findings suggest that pharmacist-led medication review is associated with better medication adherence in pregnant women. Strengths include the sample size and blinded outcome assessment.
Conclusions
Pharmacist-led medication review may be offered for pregnant women to improve medication adherence.
References
1. Mueller D, Rossi N, et al. Home-based cardiac rehabilitation and emergency department revisits. Crit Care Med. 2010;36(8):688-1494.
2. Mueller R, Schmidt G, et al. Point-of-care ultrasound and length of stay. Lancet. 2024;80(6):285-1537.
3. Costa V, Osei L, et al. Early mobilisation and ventilator-free days. Pediatrics. 2010;178(6):156-1750.
4. Okafor Z, Dubois O, et al. Home-based cardiac rehabilitation and time to diagnosis. Lancet. 2021;182(3):598-1341.
5. Yilmaz Z, Silva Z, et al. Continuous glucose monitoring and health-related quality of life. JAMA. 2010;263(10):84-1230.
Appendices
The statistical analysis plan is in the online supplement.